5 Big Winners and Losers From Earnings Season: Pfizer Inc. (PFE), Merck & Co., Inc. (MRK), Eli Lilly & Co. (LLY)

Page 1 of 2

Earnings season is a wrap for many of the brightest stars of the health care sector: Big pharma’s big disappointments and successes are in the books, and investors are looking ahead to the future. Patent expirations have been taking their toll on sales of some of the industry’s biggest blockbuster drugs lately, putting pharmaceutical firms on the defensive as they try to boost pipeline stockpiles and stave off revenue losses. With that in mind, how did five of big pharma’s biggest names grade out this earnings season?

Pfizer Inc. (NYSE:PFE)Earnings season’s big winner: Pfizer Inc. (NYSE:PFE)
After a great 2012, Pfizer Inc. (NYSE:PFE) has opened up 2013 with a bang. The company’s $11.85 billion sale of its nutrition business to Nestle last year has rewarded shareholders, as Pfizer reported fourth-quarter profit that more than quadrupled last year’s total. Earnings per share of $0.85 — drastically up from $0.19 a year ago — made investors happy, although adjusted EPS that removed one-time items fell slightly by $0.02 to $0.47; still, that beat analyst profit projections of $0.44 per share for the quarter.

All the talk now surrounds Pfizer’s recent debut of former animal health business Zoetis Inc (NYSE:ZTS) as a publicly traded company following its recent IPO, but Pfizer’s still dealing with issues of its own. The company faces plenty of generic competition for drugs — particularly blockbuster Lipitor, which lost patent protection last year — in what’s become an industrywide trend. However, with a massive pipeline of 87 drugs to bolster the future, Pfizer could make up for falling revenues, which declined 7% this past quarter, by scoring a few timely FDA approvals.

Ultimately, Pfizer could be one of the better-positioned companies for the future after it scored one of the industry’s best earnings reports, particularly as its rivals have struggled as of late.

Future imperfect: Merck & Co., Inc. (NYSE:MRK)
Fellow Dow Jones member Merck & Co., Inc. (NYSE:MRK) hasn’t had so much to cheer about recently despite a strong 2012. The company actually reported an earnings beat despite the negativity that’s surrounded it in past days; Merck’s earnings per share came in at $0.83, $0.02 higher than analysts projected, while revenue of $11.7 billion also beat expectations. Both fell from a year ago — and it’s the future, not the present, that has investors so concerned.

The company warned investors that generic competition will cut into 2013 profits as Merck continues to feel the pain from patent expirations, particularly on blockbuster drug Singulair. The company’s still got a handle on strong products for the future, such as blockbuster diabetes therapies Januvia and Janumet and fast-growing cervical cancer vaccine Gardasil — each of which posted strong  double-digit sales growth this past quarter — but the caution wasn’t what shareholders wanted to hear.

Singulair sales flopped by 67% this past quarter — and by 30% for 2012 as a whole — showing just how bad the patent cliff is hurting Merck’s sales. With the company delaying its filing for FDA approval on promising osteoporosis drug odanacatib until 2014, the year ahead for Merck has become considerably tougher.

The pain of patent losses: Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY)
Generic sales have cut a wide swath across big pharma with the patent cliff, and Eli Lilly & Co. (NYSE:LLY) and Bristol Myers Squibb Co. (NYSE:BMY) felt the pain this quarter. The former’s still feeling the pain from the 2011 patent expiration of once-blockbuster drug Zyprexa, as the drug’s sales fell 49% in the fourth quarter to under $400 million — after at one point selling more than $5 billion annually. Eli Lilly’s earnings per share fell by $0.03 year-over-year to $0.74 for the quarter, with revenue also falling around 1%. Still, the company’s numbers did manage to beat estimates. Furthermore, Eli Lilly’s pipeline holds several promising therapies in oncology and diabetes that could help the stock’s recent run-up should any of them score FDA approval and would ease the loss of patent protection on blockbuster depression drug Cymbalta this December.

Bristol-Myers managed to boost earnings per share by 12% in a delight for investors — a good thing, too, since the company’s revenue fell by an ugly 23%, with an ungodly 38% fall in U.S. sales for the quarter. Like Eli Lilly, patent losses took a bite out of the company: Sales of Avapro and Plavix, each which recently lost patent protection, especially hurt, with Plavix revenue falling a ridiculous 97% for the quarter.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!